Batabulin sodium(Synonyms: T138067 sodium)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Batabulin sodium (Synonyms: T138067 sodium) 纯度: 99.79%

Batabulin sodium (T138067 sodium) 是一种抗肿瘤剂，可与 β-微管蛋白同种型的子集共价且选择性地结合，从而破坏微管 (microtubule) 聚合。Batabulin sodium 影响细胞形态并导致细胞周期停滞，最终诱导凋亡性细胞死亡。

Batabulin sodium(Synonyms: T138067 sodium)

Batabulin sodium Chemical Structure

CAS No. : 195533-98-3

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥1980 In-stock
5 mg ￥1800 In-stock
10 mg ￥2700 In-stock
50 mg ￥6800 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Batabulin sodium 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Cytoskeleton Compound Library
  • Anti-Lung Cancer Compound Library
  • Targeted Diversity Library

生物活性

Batabulin sodium (T138067 sodium) is an antitumor agent, which binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Batabulin sodium affects cell morphology and leads to cell-cycle arrest ultimately induces apoptotic cell death[1].

IC50 & Target

β-tubulin[1]
体外研究
(In Vitro)

Batabulin (T138067; 30-300 nM; 24 hours; MCF7 cells) treatment shows approximately 25-30% tetraploid (4n) DNA content in cells, indicating an arrest at the G2/M cell-cycle boundary[1].
Batabulin (T138067; 30-300 nM; 24-48 hours; MCF7 cells) treatment shows 25-30% apoptosis. After a 48-hr exposure to 100 nM Batabulin, approximately 50-80% of the cell population is undergoing apoptosis[1].
Batabulin (T138067) binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Covalent modification occurs at a conserved Cys-239 shared by the β1, β2, and β4 tubulin isotypes. Cells exposed to Batabulin become altered in shape, indicating a collapse of the cytoskeleton, and show an increase in chromosomal ploidy[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[1]

Cell Line: MCF7 cells
Concentration: 30 nM, 100 nM and 300 nM
Incubation Time: 24 hours
Result: Showed an arrest at the G2/M cell-cycle boundary.

Apoptosis Analysis[1]

Cell Line: MCF7 cells
Concentration: 30 nM, 100 nM and 300 nM
Incubation Time: 24 hours or 48 hours
Result: 25-30% of cells showed the reduced DNA content characteristic of apoptotic cells.

体内研究
(In Vivo)

Batabulin (T138067; 40 mg/kg; intraperitoneal injection; once per week; on days 5, 12, and 19; male athymic nude mice) treatment impairs the growth of the drug-sensitive CCRF-CEM tumors[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male athymic nude mice (nu/nu) (6-8 week-old, 20-25 g) injected with CCRF-CEM cells[1]
Dosage: 40 mg/kg
Administration: Intraperitoneal injection; once per week; on days 5, 12, and 19
Result: Impaired the growth of the drug-sensitive CCRF-CEM tumors.

Clinical Trial

分子量

393.24

Formula

C13H6F6NNaO3S
CAS 号

195533-98-3
中文名称

巴他布林酸钠
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (317.87 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5430 mL 12.7149 mL 25.4298 mL
5 mM 0.5086 mL 2.5430 mL 5.0860 mL
10 mM 0.2543 mL 1.2715 mL 2.5430 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Shan B, et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5686-91.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务